Enabling Transformation in Life Sciences Through Digital Health Solutions
January 5th 2022At a time when life sciences companies have seen an unprecedented acceleration in the adoption of digital tools, many are now faced with managing a myriad of tools and applications with varying levels of security and technology requirements. Biopharma and medical device manufacturers are now exploring solutions and platforms that can provide the stability, regulatory compliance, and end-to-end connectivity needed to design, deliver and scale digital solutions that deliver clinical and economic benefits to patients, providers and payers. In this session, Brian Williams, Chief Digital Officer for Life Sciences at Cognizant, will discuss the opportunity available to digital-first companies that are considering cloud platforms like Philips HealthSuite, which is built on Amazon Web Services.
Studying Long COVID in Drug Development
October 13th 2021As the initial COVID-19 pandemic begins to resolve in the form of vaccines and treatment pathways, research into the long-term effects of COVID is building. In response, in December, Congress provided $1.15 billion in funding over four years for NIH to support research into the prolonged health consequences of SARS-CoV-2 infection. This roundtable of experts from various stakeholder groups will discuss the current research into long-haul COVID, or PASC; disparate theories of causes; challenges in research and diagnosis, as well as PASC potential in drug development.
Addressing Roadblocks in Decentralized Trials
May 18th 2021In a recent virtual roundtable discussion, industry experts Jim Streeter, Alison Holland, Hassan Kadhim, Craig Lipset, Josh Rose, and Craig Serra shared their insight on the challenges faced in implementing decentralized trials and how to address them. Along with the roundtable are video discussions covering the cost and feasibility of a toolkit approach to decentralized trials, the significance of minimizing burden to patients and sites, and the reality of regulatory hurdles.